Cutaneous Lupus Erythematosus Induced by Tislelizumab
April 2024
in “
JDDG Journal der Deutschen Dermatologischen Gesellschaft
”
Studysummary In this case report, the authors concluded that cutaneous lupus erythematosus was induced by the PD-1 inhibitor tislelizumab during treatment for metastatic lung adenocarcinoma, despite initial remission and treatment adjustments. Our plain-language summary of this paper — not a Tressless recommendation.
A 69-year-old Asian male developed cutaneous lupus erythematosus (CLE) after receiving 10 cycles of tislelizumab, a PD-1 inhibitor, for metastatic lung adenocarcinoma. The patient presented with pruritic erythematous plaques, which worsened upon resuming tislelizumab after a 3-month break. Laboratory tests showed positive antinuclear and anti-SSA/Ro antibodies, and histology confirmed CLE. Treatment with oral prednisone, hydroxychloroquine, and topical steroids led to significant improvement after 14 weeks, though some hypopigmentation and scarring remained. This case highlights the potential for tislelizumab to induce CLE, an immune-related adverse event, and underscores the need for further research on immune checkpoint inhibitors and lupus erythematosus.
